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cm, p = 0.008, respectively). Insulin resistance also decreased 
after metformin therapy (4.5 ± 1.9 vs. 2.9 ± 1.7, p < 0.0001). 
The mean thyroid volume (22.5 ± 11.2 vs. 20.3 ± 10.4 ml, p < 
0.0001) and mean thyroid nodule size (12.9 ± 7.6 vs. 11.7 ± 
7.2 mm, p < 0.0001) also decreased after treatment.  Conclu-
sion: In subjects with insulin resistance, metformin therapy 
significantly decreased thyroid volume and nodule size. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Previous studies have reported the effect of insulin re-
sistance (IR) on thyroid volume and nodule prevalence 
 [1, 2] . The concept that insulin concurrently functions 
with thyroid-stimulating hormone (TSH) as a growth 
factor and stimulates thyroid cell proliferation  [3] has 
also been reported. This proliferative effect on thyrocytes 
is partially mediated via insulin-like growth factor 1 
(IGF-1)-dependent mechanisms; therefore, IGF-1 might 
be involved in the pathogenesis of thyroid morphological 
abnormalities  [3, 4] . There is now considerable evidence 
that these hormones and the signal transduction mecha-
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 Abstract 
 Objective: The aim of this study was to investigate the ef-
fects of metformin on thyroid volume and nodule size.  Sub-
jects and Methods: Prospective data were gathered on 100 
newly diagnosed subjects with insulin resistance (68 female, 
32 male) between August 2008 and May 2010. Each subject 
followed a standard diet and exercise program, and received 
1,700 mg/day of metformin therapy for 6 months. The 
height, weight, waist circumference (WC) and thyroid hor-
mone levels of each subject were measured. Additionally, 
the dimensions of the thyroid lobes and maximum diameter 
of each thyroid nodule were determined by ultrasonogra-
phy. BMI and thyroid volumes were also calculated. Insulin 
resistance was estimated by homeostasis model assess-
ment. All these parameters were measured at the beginning 
and at the end of the treatment period.  Results: BMI and WC 
decreased significantly after metformin therapy (34.5 ± 5.1 
vs. 32.7 ± 4.8, p < 0.0001, and 106.3 ± 11.8 vs. 101.8 ± 19.0 
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nisms they regulate are modulated by metformin therapy 
 [5–7] . Preclinical and clinical data supporting the anti-
proliferative effects of metformin provide the rationale to 
study its role in thyroid morphology  [8, 9] . This may lead 
to metformin becoming a potential therapeutic agent for 
benign and malignant thyroid overgrowths. The objec-
tive of the current study was to examine the effects of 
metformin therapy on thyroid volume and nodule size. 
 Subjects and Methods 
 Study Subjects 
 This was a single-center, prospective interventional trial in eu-
thyroid subjects with IR. The Baskent University Ethics Commit-
tee for Human Studies approved the protocol and all participants 
provided written informed consent. The study population con-
sisted of 100 subjects with IR (68 females and 32 males, age range 
22–74 years) referred to our institution for workup of obesity be-
tween August 2008 and May 2010.
 Euthyroidism was defined as TSH (reference range 0.35–4.0 
mIU/l), free tri-iodothyronine (FT3; reference range 1.71–4.71 pg/
ml) and free tetra-iodothyronine (FT4; reference range 0.8–1.9 ng/
dl) within the normal reference range. The inclusion criterion was 
age between 18 and 75 years. Exclusion criteria were subjects with 
a history of thyroid disease, overt or subclinical hyperthyroidism 
and hypothyroidism (as defined by suppressed or elevated TSH 
levels, respectively), previous thyroxine suppression therapy at any 
time, high thyroid autoantibody titers or a history of neck irradia-
tion or surgery.
 Subjects with the following confounding factors on thyroid ul-
trasonography were ruled out as an important step in achieving a 
more homogenous study population: retrosternal goiter, thyroid 
volume more than 40 ml, and coalescent thyroid nodules (not suit-
able for size analysis). The smallest thyroid nodule considered for 
size analysis was  ≥ 5 mm in the maximum diameter at baseline. 
Colloid cysts and pure thyroid cysts were not included in the size 
analysis. Patients were also excluded if they exhibited endocrine 
obesity, diabetes mellitus, pregnancy or lactation, hepatic or renal 
dysfunction, and a history of heart failure or significant neuro-
logical or psychological illness (depression, epilepsy, schizophre-
nia) that would have an impact on thyroid function tests. 
 The study subjects were prescribed a standard hypocaloric diet 
and regular standard aerobic exercise under the supervision of a 
dietician who monitored them periodically. Each subject received 
1,700 mg/day of metformin therapy during the study period.
 Anthropometric Measurements 
 The height, weight and waist circumference (WC) of each sub-
ject were recorded by the same physician (A.G.). WC was mea-
sured with a folding tape at the natural waistline (the level of the 
umbilicus) in a horizontal plane. BMI was calculated by the body 
weight in kilograms divided by the square of the height in meters 
(kg/m 2 ). 
 Thyroid Function and Morphology 
 Thyroid ultrasonography was performed by a single physician 
(A.G.), who was blinded to patient diagnosis and therapy, using a 
10-MHz linear probe (Logiq 5 Pro, GE Medical Systems, Wauke-
sha, Wis., USA) before and 6 months after metformin therapy. 
Thyroid gland volumes were calculated according to the ellipsoid 
formula: volume (ml) = depth (cm) × width (cm) × length (cm) × 
π/6  [10] . The diameters of 65 nodules were measured in three di-
mensions and the largest diameter was recorded for each thyroid 
nodule. 
 Laboratory Analysis 
 Venous blood samples were drawn after a minimum fasting 
period of 12 h at baseline and 6 months after metformin therapy. 
All blood samples were collected between 08: 00 and 09: 00 h. Thy-
roid function was evaluated by measuring FT4, FT3 and TSH us-
ing immunochemiluminescent assays by an automated analyzer 
(Immulite 2000; Diagnostic Products Corp., Los Angeles, Calif., 
USA). Thyroid antibodies (antithyroid peroxidase, normal range 
<50 U/ml, and antithyroglobulin, normal range <40 U/ml) were 
measured by immunochemiluminescent assays using commercial 
kits (Diagnostic Products Corp.). IR was estimated based on the 
calculation of the homeostasis model assessment (HOMA) index 
for each patient. This was done using the formula: fast-
ing plasma insulin (IU/ml) × fasting plasma glucose (mmol/l)/
22.5  [11] .
 Serum glucose was measured by the glucose oxidase technique 
(Roche Diagnostics GmbH, Mannheim, Germany). The serum in-
sulin level was assayed with a solid-phase competitive chemilumi-
nescent enzyme immunoassay (Diagnostic Product Corp.).
 Statistical Analysis  
 All continuous data were expressed as the mean ± SD. Data 
were analyzed with SPSS software (Statistical Package for the So-
cial Sciences, version 11.0, SSPS Inc., Chicago, Ill., USA). Statisti-
cal comparisons were performed by means of independent-sam-
ple t tests for data with a normal distribution and χ 2 tests for per-
centages. Pearson’s correlation test was performed for the 
correlation analysis. A p value <0.05 was considered statistically 
significant.
 Results 
 Anthropometric, biochemical and thyroid ultrasonog-
raphy data are summarized in  table 1 . The mean BMI and 
WC decreased significantly after metformin therapy (34.5 
± 5.1 vs. 32.7 ± 4.8, p < 0.0001, and 106.3 ± 11.8 vs. 101.8 
± 19.0 cm, p = 0.008, respectively). IR as estimated by 
HOMA also decreased after metformin therapy (4.5 ± 1.9 
vs. 2.9 ± 1.7, p < 0.0001).
 Thyroid Function and Morphology 
 After metformin therapy, mean serum concentrations 
of TSH decreased (1.8 ± 1.0 vs. 1.5 ± 0.8 mIU/l, p < 0.0001) 
and mean serum concentrations of FT3 increased (2.7 ± 
0.7 vs. 3.0 ± 0.8 pg/ml, p = 0.03) significantly. Mean FT4 
values were similar before and after metformin therapy 
(1.4 ± 0.6 vs. 1.5 ± 1.3 ng/dl, p > 0.5).
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 The mean thyroid volume was significantly reduced 
after metformin therapy (22.5 ± 11.2 vs. 20.3 ± 10.4 ml, 
p < 0.0001). The mean thyroid nodule size was also sig-
nificantly decreased after metformin therapy (12.9 ± 7.6 
vs. 11.7 ± 7.2 mm, p < 0.0001); 65 patients had thyroid 
nodules  ≥ 5 mm (satisfying one of the inclusion criteria 
for admission) at the beginning, which decreased to 56 
after metformin therapy (p = 0.004). There was no sig-
nificant correlation between TSH and thyroid volume 
and nodule prevalence before and after metformin ther-
apy (p > 0.05, r = 0.2).
 Discussion 
 In this study, thyroid volume and probably the nodule 
prevalence decreased after metformin therapy. At base-
line and after metformin therapy, there was no significant 
correlation between TSH and thyroid volume which 
could suggest that TSH-independent mechanisms might 
be involved in thyroid cell proliferation in subjects 
with IR.
 In a previous report by Rezzonico et al.  [1] , patients 
with IR had larger thyroid volumes and a higher risk for 
the formation of thyroid nodules. They concluded that 
the higher circulating levels of insulin cause increased 
thyroid proliferation and thyroid nodules.
 Our current and previous data suggest that IR and hy-
perinsulinemia per se may contribute to an increased thy-
roid volume and nodule prevalence and an improvement 
of insulin sensitivity by metformin therapy acting to ame-
liorate these morphological abnormalities  [2] . IGF-1 is 
actively involved in the TSH-mediated proliferation of 
thyrocytes. The insulin/IGF-1 signaling pathway has long 
been known to modulate the regulation of thyroid gene 
expression and might be considered an additional impor-
tant factor in thyrocyte proliferation and differentiation 
 [3, 4] . It cannot be excluded that metformin has a direct, 
antiproliferative effect on the thyroid, possibly by sup-
pressing mTOR activity, which might contribute to these 
observed effects  [8] .
 In a similarly designed study by Rezzonico et al.  [9] , 
66 women with IR and nodular goiter were assigned to 
one of four interventional groups which consisted of 
treatment with metformin alone, metformin and levo-
thyroxine, levothyroxine alone, and a control group. Sig-
nificant reductions in nodule size were observed in the 
groups treated with metformin in parallel with improve-
ments in IR, and the other two groups demonstrated no 
change.
 Vigersky et al.  [6] reported for the first time that treat-
ment with metformin caused suppression of TSH to sub-
normal levels without clinical symptoms of hyperthy-
roidism, which was confirmed in the present study. Al-
though the mechanism of the fall in serum TSH is unclear 
at this time, similar observations have been reported in 
the literature  [7] . However, in a retrospective but large 
cohort of euthyroid diabetic patients, Díez and Iglesias 
 [12] did not find any significant relationship between 
TSH and metformin treatment.
 IR increases visceral fat accumulation and this vis-
ceral fat increases TSH secretion as a result of a resetting 
of the hypothalamic-pituitary thyrostat operated by the 
adipose tissue  [13] . There is evidence in the literature 
indicating that a possible relationship exists between 
leptin and the thyroid hormones via an influence of 
leptin on the negative feedback regulation of thyroid 
hormones and TRH expression  [13, 14] . Leptin secre-
tion increases exponentially with increasing fat mass 
and insulin also increases total leptin levels  [14] . Thus, 
increased fat mass along with IR may contribute to in-
creased serum TSH levels via effects on serum leptin 
concentrations  [13, 14] . Serum FT3 concentrations are 
also lower in leptin-deficient subjects  [13] . In animal 
studies, metformin increased the leptin receptor gene 
expression in the arcuate nucleus, suggesting that the 
TSH- and possibly FT3-modulating effect of metformin 
is potentially mediated via an increase in the central sen-
sitivity to leptin  [15] . The major limitation of this study 
was the lack of a control group. However, this research 
was designed as a preliminary study due to its unique 
layout.
 Table 1.  Clinical, laboratory and thyroid ultrasonography charac-
teristics of study subjects before and after metformin therapy
At baseline After 
metformin
p value
Male/female 32/68 – –
Age, years 52.5 ± 10.3 – –
BMI 34.5 ± 5.1 32.7 ± 4.8 <0.0001
WC, cm 106.3 ± 11.8 101.8 ± 19.0 <0.01
HOMA-IR 4.5 ± 1.9 2.9 ± 1.7 <0.0001
Thyroid volume, ml 22.5 ± 11.2 20.3 ± 10.4 <0.0001
Mean nodule size, mm 12.9 ± 7.6 11.7 ± 7.2 <0.0001
TSH, mIU/l 1.8 ± 1.0 1.5 ± 0.8 <0.0001
FT3, pg/ml 2.7 ± 0.7 3.0 ± 0.8 <0.05
FT4, ng/ml 1.4 ± 0.6 1.5 ± 1.3 >0.5
Nodule (≥5 mm), % 65.0 56.0 <0.01
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 Conclusion 
 This preliminary study showed that metformin ad-
ministration in subjects with IR was associated with a sig-
nificant reduction in thyroid volume and nodule size. The 
drug therapy also decreased the serum levels of TSH and 
increased the serum levels of FT3, with no change in FT4. 
Future studies could reveal some novel aspects of the 
pathophysiology of goiters.
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